Atara Biotherapeutics, Inc.ATRA
Price (close)
$8.81
Market cap
$83.2M
P/E
—
Revenue (TTM)
$6.2M
Net income
-$16.7M
Dividend yield
—
1-year total return
-36.3%
Net margin
-269.4%
Revenue growth
-96.7%
Debt / equity
—
What Atara Biotherapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $63.6M | $8.6M | $128.9M | $120.8M |
| Net income | -$306.6M | -$340.1M | -$228.3M | -$276.1M | -$85.4M | $32.7M |
| Free cash flow | -$185.3M | -$231.1M | -$274.6M | -$194.2M | -$69.0M | -$50.9M |
More on ATRA.
- Atara Biotherapeutics, Inc. summary
- Atara Biotherapeutics, Inc. financial statements
- Atara Biotherapeutics, Inc. key metrics
- Atara Biotherapeutics, Inc. health scores and style box
- Atara Biotherapeutics, Inc. earnings
- Atara Biotherapeutics, Inc. dividends
- Atara Biotherapeutics, Inc. valuation
- Atara Biotherapeutics, Inc. ownership and insiders
- Atara Biotherapeutics, Inc. peers
Figures from Atara Biotherapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.